UY39593A - TREATMENT FOR MALIGNANT SOLID TUMORS - Google Patents

TREATMENT FOR MALIGNANT SOLID TUMORS

Info

Publication number
UY39593A
UY39593A UY0001039593A UY39593A UY39593A UY 39593 A UY39593 A UY 39593A UY 0001039593 A UY0001039593 A UY 0001039593A UY 39593 A UY39593 A UY 39593A UY 39593 A UY39593 A UY 39593A
Authority
UY
Uruguay
Prior art keywords
solid tumors
treatment
malignant solid
subject
malignant
Prior art date
Application number
UY0001039593A
Other languages
Spanish (es)
Inventor
Gajanan Bhat
Lyndah Dreiling
Sribalaji Lakshmikanthan
A Barrett John
Francois Lebel
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY39593A publication Critical patent/UY39593A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento, se describe un método para tratar tumores sólidos en un sujeto. El método en general incluye administrar una cantidad terapéuticamente eficaz de poziotinib o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite.Herein, a method of treating solid tumors in a subject is described. The method generally includes administering a therapeutically effective amount of poziotinib or a pharmaceutically acceptable salt thereof to a subject in need thereof.

UY0001039593A 2020-12-29 2021-12-28 TREATMENT FOR MALIGNANT SOLID TUMORS UY39593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063199445P 2020-12-29 2020-12-29
US202163166748P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
UY39593A true UY39593A (en) 2022-07-29

Family

ID=82259660

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039593A UY39593A (en) 2020-12-29 2021-12-28 TREATMENT FOR MALIGNANT SOLID TUMORS

Country Status (3)

Country Link
TW (1) TW202237122A (en)
UY (1) UY39593A (en)
WO (1) WO2022147150A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019376A2 (en) * 2019-03-29 2021-12-07 Univ Texas Compounds with antitumor activity against cancer cells carrying her2 exon 21 insertions
CN113939284A (en) * 2019-03-29 2022-01-14 得克萨斯大学体系董事会 Compounds with anti-tumor activity against cancer cells carrying EGFR or HER2 exon 20 insertion
TW202211923A (en) * 2020-07-27 2022-04-01 美商光譜製藥公司 Treatment of non-small cell lung cancer with poziotinib

Also Published As

Publication number Publication date
WO2022147150A1 (en) 2022-07-07
TW202237122A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
CL2021002267A1 (en) Methods for treating cancers and enhancing the efficacy of therapeutic agents for t-cell retargeting. (request divisional 202002945)
CO2021015318A2 (en) Compounds and methods for the treatment of covid-19
CO2020013600A2 (en) Treatment of hidradenitis suppurativa using jak inhibitors
AR072442A1 (en) METHOD FOR CANCER THERAPY, USE, KIT
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
CL2021002533A1 (en) Compositions and methods for treating diseases or disorders associated with kras
WO2018102687A3 (en) Combination therapy for treating cancer
CL2022003511A1 (en) Alk2 inhibitors for the treatment of anemia.
CL2020002544A1 (en) Ret inhibitor for use in treating cancer that has a ret alteration
AR119159A1 (en) ANGIOEDEMA TREATMENTS
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
CL2023000857A1 (en) Line-1 inhibitors to treat the disease
CL2022000781A1 (en) Medicinal cognitive treatments
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
MX2021015447A (en) Methods of treating cancer by targeting cold tumors.
BR112021020962A2 (en) Pruritus treatment methods
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA
EA202190457A1 (en) CONJUGATES FOR USE IN METHODS FOR TREATMENT OF CANCER
MX2021007565A (en) Compositions and methods for cancer therapy.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CL2021001623A1 (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer
UY39593A (en) TREATMENT FOR MALIGNANT SOLID TUMORS
CL2021003303A1 (en) Treatment for synucleinopathies.
AR118933A1 (en) KRAS INHIBITOR DOSAGE FOR THE TREATMENT OF CANCER
AR122301A1 (en) METHODS TO TREAT GASTROINTESTINAL STROMAL TUMORS